ELSEVIER

Contraception
1996;54:389–390

Author Index
Volume 54
July–December

Abdel-Aleem, H., 281
Abol-Oyoun, E-S.M., 281
Adekunle, A.O., 313
Alvarez, F., 275, 313
Athayde, C., 313
Azzini, M., 149

Bahamondes, L., 159, 287
Baird, D.T., 97
Baldwin, D.M., 43
Baltaro, F., 163
Barbosa, I., 313
Barbosa, I.C., 213
Bardin, C.W., 253
Baumann, A., 235
Beisiegel, U., 291
Berglund, S., 359
Bernardi, F., 149
Biswas, A., 91
Bourinbaiar, A.S., 367
Brache, V., 275
Brill, K., 299
Brocco, G., 149
Brudny-Kløppel, M., 235
Bruppacher, R., 5
Bunte, D., 235
Burke, A.E., 19

Chan, K.S., 23
Chang, C.L., 193
Changmin, Z., 345
Chaturachinda, K., 87, 305
Chauhan, S.C., 259
Chi, I.-c., 33
Clark, S., 323
Coeling, H.J., 333
Cole, L.P., 181
Correa, J.R., 39
Corrocher, R., 149
Costa, R.G., 159
Coutinho, E.M., 213, 313
Creinin, M.D., 15, 19
Croisignani, P.G., 271
Croxatto, H.D., 79
Croxatto, H.B., 79
Csemiczky, G., 333
Cuong, D.T., 169

d'Arcangues, C., 153
Dao, B., 253
de Mouzon, J., 55
de Acosta, A.M., 313
Devendra, K., 373
Devoto, L., 313
Diaz, J., 287
Dieben, T., 333
Digenis, G.A., 39
Dikkeschei, L.D.,153
Draeger, C., 235
Dunson, T.R., 33
Düsterberg, B., 71

El-Saeed, M., 281
Ellertson, C., 323
Elomaa, K., 187
Elstein, M., 71
Emuveyan, E.E., 313

Falkay, G., 27
Farley, T.M.M, 193
Faùndes, A., 159
Faundes, A., 275
Fàundes, D., 287
Feichtinger, W., 71
Feichtinger, W., 299
Forest, M.G., 153
Fotherby, F., 59
Földesi, I., 27
Franceschi, S., 101
Frank, E., 319
Friso, S., 149
Fritzemeier, K-H, 243
Fuentealba, B., 79
Fuhrmann, U., 243
Fuhrmeister, A., 235

García, J., 359
Girelli, D., 149
Goliang, S., 345
Gorini, G., 163
Graf, A.H., 309
Grazioli, S., 149
Gruber, A., 117
Grummer-Strawn, L., 339
Gu, Q.Q., 107

Halvorsen, L.E., 209
Hannaford, P.C., 125
Hardy, E., 159
Heikinheimo, O., 229
Heinemann, L.A.J., 5
Hendrickx, A.G., 107
Hirsch, C., 213
Ho, P.C., 23

Ilavazhagan, G., 373
Intaraprasert, S., 87, 305

Jamin, C., 55
Jene, A., 291

Kahn, H., 209
Kamboj, V.P., 259
Kaplan, B., 117
Kekkonen, R., 229
Keqiang, L., 345
Kigondu-Sekadde, C.B., 153
Kindermann, Ch., 299
Koh, S.C.L., 219
Koide, S.S, 253
Kovàcs, L., 27
Krattenmacher, R., 243
Kriengsinyot, R., 153
Kuhnz, W., 235

La Vecchia,.C., 101
Ladipo, D.A., 213
Lähteenmäki, P., 79, 187, 201, 229
Lamprecht, V.M., 339
Landgren, B.-M., 333
Lapido, O.A., 313
Lasley, B.L., 43, 107
Laufe, L.E., 181
Laughiln, L.S., 43
Lee, C-H, 131, 367
Leepipatpaiboon, S., 153
Leidenberger, E., 291
Leong, W.P., 91
Lewis, M.A., 5
Lidegaard, O., 195
Liljestrand, J., 359
Lin, L. 345
Lippert, T.H., 265
Lorkowski, G., 265
Lüdicke, F., 71
Lunghi, B., 149
Luukkainen, T., 187
Lynch, P., 97

Ma, G.-T., 33
MacRae, K.D., 5
Mahommadi, F., 39
Maitra, S.C., 259

© 1996 Elsevier Science Inc. All rights reserved.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/96/$15.00
PII S0010-7824(96)00272-7

Makhlouf, A., 281
Mandelin, E., 229
Manzato, F., 149
Marmot, M.G., 193
Marshall, A., 253
Martin, A., 309
Massai, M.R., 79
Mati, J.K.G., 153
Mati, J.M., 313
Matlin, S.A., 107
Meirek, O., 193
Milsom, I., 195
Monaco, A., 163
Muia, P.N., 153
Müller, U., 71
Munro, C.J., 43
My Huong, N.T., 169
Mück, A.O., 265

Negri, E., 101
Neri, A., 117
Ngal, C.S.W., 23
Nordbø, S.A., 209
Nosek, D., 39

Olivieri, O. 149
Olsson, S.E., 213
Osis, M.J., 159

Pakarinen, P., 187
Parazzini, F., 101, 271
Pardo, J., 117
Peña, R., 359
Persson, L.A., 359
Petta, C.A., 287
Piazzi, G., 163
Pimentel, E., 287
Poulter, N.R., 193
Premakumara, G.A.S, 379

Qifu, F., 345

Rabinerson, D., 117
Ratnam, S.S., 91, 219
Ratnasooriya, W.D., 379
Ratsula, K., 187
Ricci, E., 101
Rivera, R., 33
Rosenblatt, K.A., 329
Russo, C., 149

Saake, K., 209
SaiRam, M., 373
Salem, H.T., 281
Salvatierra, A.M., 79
Schenken, R.S., 181
Seeger, H., 265
Selvamurthy, W., 373
Shaaban, M.M., 281
Sharma, S.K.,373
Shi-Zhong, W., 345
Shivaji, S.S., 373
Shoukry, M., 281
Shoupe, D., 181
Singh, M.M, 259
Skjeldestad, F.E., 209
Slater, E.p., 243
Sokal, D.C., 181
Spinillo, A., 163
Spitzer, W.O., 5
Spitzer, D., 309
Spona, J., 71, 299
Staudach, A., 309
Steiner , H., 309
Suisaari, J., 201
Sullivan, H., 71

Taneepanichskul, S., 305
Taneepanichskul, S., 87
Tang, L.C.H, 23
Tarantal, A.F., 107

Teichmann, A.T., 265
Tejada, A.S., 275
Testa, G., 271
Then, A., 291
Thevenin, F., 275
Thomas, D.B., 329
Thomas, C.A.A., 107
Thong, K.J., 97
Tilekeratne, L.M.V., 379
Tuominen, J., 187

Ulmsten, U., 213

Van Look, P.F.A, 107
Vanage, G., 253
Vegetti, W., 271
Venesmaa, P., 187
Vichaidith, P., 153
Viegas, O.A.C., 91, 219
Vince, P.M., 107
Virtuamasen, P., 153
VonSchaischa, T., 43

Webb, A.M.C, 125
Westhoff, C.L., 1
White, R., 319
Winikoff, B., 323
Wolthers, B.G.,153
Wong, K.S., 33
Wünch, C., 291

Xu, J.-X., 33

Yang, X.-L., 33

Zara, F., 163
Zavos, P.M., 39
Zelaya, E., 359
Zhi-Ping, G., 313
Zhuang, L.-Q., 33

ELSEVIER

Contraception
1996;54:391–393

Subject Index
Volume 54
July–December 1996

Acceptability,
  methotrexate + misoprostol, 19
  Uniplant contraceptive implant, 313
Activated protein C-resistance status, effect of OC use, 149
Anti-implantation activity,
  antiestrogens (rat), 253
  RU 486 (rat), 253
Antiestrogens, anti-implantation activity (rat), 253

Basal body temperature method, 319
Bias in observational research, OCs, 5
Bioavailability, sex steroids, 59
Biochemical profile,
  drospirenone, 243
  progesterone, 243
Bleeding patterns,
  copper IUD, 201
  levonorgestrel-releasing intrauterine system, 201
  Norplant-2 implants, 91
Breast cancer and hormonal contraceptives, supplement (Supplement 1S–106S)
Breast-fed infants, effect of depot-medroxyprogesterone acetate, 153

C. trachomatis screening, IUD insertion, 209
Calcium influx and contraceptives, 265
Calendar method formulas, 339
Cervical mucus, effect of nomegestrol acetate, 213
Chamydial infection, effect of contraceptive use, 163
Clinical decision-making, OC use, 1
Clinical study, levonorgestrel-releasing intracervical device, 187
Clinical trial, injectable contraceptives, 169Combined OC use,
  screening procedures, 125
  risk of breast cancer, supplement 13S
Contraceptive activity, marine red algae extract (rat), 379
Contraceptive potential, RU 486 + medroxyprogesterone acetate, 79
Contraceptive use, effect on chlamydial infection, 163
Contraceptive use patterns, 359
Contraceptives and calcium influx, 265
Copper-releasing IUD, bleeding patterns, 201

Depot-medroxyprogesterone acetate,
  clinical trial, 169
  effect on male infants, 153
Drospirenone, biochemical profile, 243

EDTA + gramicidin, effect on sperm motility, 367
Endometrial cancer, IUD use, 329
Enzyme immunoassay, levonorgestrel, 43
Estradiol + desogestrel, pharmacodynamic effects, 239
Estradiol cypionate + depot-medroxyprogesterone acetate, clinical trial, 169
Estrogens, bioavailability, 59
Ethinylestradiol, pharmacokinetics, 235
Ethinyl estradiol + desogestrel, 271
Ethinylestradiol + gestodene, 71, 291
Ethinylestradiol + levonorgestrel, 299
Evidence-guided prescribing, combined OCs, 125

Failure analysis,
  medical abortion, 323
  surgical abortion, 323
Fertile time, calendar method formulas, 339
Filshie clips, sterilization, 309
First generation OCs, 5

Gemeprost + misoprostol, pregnancy termination, 23
Gemeprost + RU 486, pregnancy termination, 97
Gestogens, bioavailability, 59
Gramicidin + EDTA, effect on sperm motility, 367

Haemostatic parameters, effect of levonorgestrel, 219
HIV-1 positive women, laparoscopic sterilization, 305
Hormonal contraceptives and breast cancer, Supplement, 1S–106S
HRP 2000 antiprogestin, effect on pregnancy (monkey), 107

Immediate postplacental insertion, TCu 380A, 33
Implant contraceptive,
  levonorgestrel, 91, 219, 275
  nomegestrol acetate, 213, 281, 313
In vitro spermicidal tests, review, 131
Injectable contraceptive,
  depot-medroxyprogesterone acetate, 169, 153
  estradiol cypionate + depot-medroxyprogesterone acetate, 169
Intracervical device, levonorgestrel-releasing, 187
Intrauterine device (IUD),
  levonorgestrel-releasing, 201
  management of missing device, 117
  Nova-T, 201
  TCu 380A, 33
IUD insertion, screening for *C. trachomatis*, 209
IUD use, risk of endometrial cancer, 329

© 1996 Elsevier Science Inc.
655 Avenue of the Americas, New York, NY 10010

ISSN 0010-7824/96/$15.00
PII S0010-7824(96)00261-1

Lactation, effect of nomegestrol acetate, 281
Laparoscopic sterilization, HIV-1 positive women, 305
Levonorgestrel,
  effect on bleeding patterns, 91
  effect on ovarian function, 275
  enzyme immunoassay, 43
  haemostatic effects, 219
Levonorgestrel-releasing intracervical device, 187
Levonorgestrel-releasing intrauterine system, bleeding patterns, 201
Lipid metabolism, effect of ethinylestradiol + gestodene, 291

Male infants, effect of depot-medroxyprogesterone acetate in breast milk, 153
Management of missing IUD, 117
Marine red algae extract, contraceptive activity (rat), 379
Medical abortion, analysis of failure, 323
Methotrexate + misoprostol,
  acceptability, 19
  pregnancy termination, 15, 19
Mifepristone (RU 486)
Misoprostol + gemeprost, pregnancy termination, 23
Misoprostol + methotrexate, pregnancy termination, 15, 19

Neem oil fraction, spermicidal action, 373
NIM-76,
  fraction isolated from neem oil, 373
  spermicidal action, 373
Nomegestrol acetate,
  effect on cervical mucus, 213
  effect on lactation, 281
Nomegestrol acetate implant, user satisfaction, 313
Nonoxynol-9, effect on sperm motility, 367
Nonoxynol-9 oligomers, spermicidal activity, 39
Norplant implants, 87, 275
Norplant implants removal, modified needle elevation technique, 87
Norplant-2 implants, 91, 219

OC use,
  effect on activated protein C-resistance status, 149
  effect on chlamydial infection, 163
  venous thromboembolism, 1, 5, 55, 193
OC users, characteristics, 101
OCs and venous thromboembolism, 1, 5, 55, 193
Onapristone, effect on uterine cells (rat), 259
Oral contraceptive (OC),
  estradiol + desogestrel, 239
  ethinylestradiol + gestodene, 71, 291
  ethinylestradiol + levonorgestrel, 299
  triphasic ethinyl estradiol + desogestrel, 271
Ormeloxifene, effect on uterine cells (rat), 259
Ovarian function,
  effect of estradiol + desogestrel, 239
  effect of ethinyl estradiol + desogestrel, 271
  effect of levonorgestrel, 275
  length of pill-free interval, 71
Ovulation,
  effect of ethinylestradiol + levonorgestrel, 299
  effect of RU 486 + medroxyprogesterone acetate, 79

Patterns of contraceptive use, 359
Pharmacodynamic effects, estradiol + desogestrel, 239
Pharmacokinetics,
  ethinylestradiol, 235
  new estrogens ZK 136295 and ZK 115194, 235
  RU 486, 27, 229
Pill-free interval, 7 vs. 5 days, 71
Postpartum insertion, TCu 380A, 33
Postpartum sterilization, Filshie clips, 309
Pregnancy,
  effect of HRP 2000 (monkey), 107
  effect of RU 486 (monkey), 107
Pregnancy termination,
  methotrexate + misoprostol, 15, 19
  misoprostol + gemeprost, 23
Progesterone, biochemical profile, 243
Progestogen-only contraceptives use, risk of breast cancer, supplement, 23S
Psychological effects, sterilization, 345

Quinacrine pellets, transcervical administration, 181

Radioimmunoassay, levonorgestrel, 43
Reformulated Norplant-2 implants, 219
Removal Norplant implants, modified needle elevation technique, 87
Reproductive factors, OC use, 101
Risk of breast cancer,
  use of combined OCs, supplement, 12S
  use of progestogen-only contaceptives, supplement, 23S
RU 486 (mifepristone),
  anti-implantation activity (rat), 252
  effect on pregnancy (monkey), 107
  pharmacokinetics, 27, 229
RU 486 + gemeprost, pregnancy termination, 97
RU 486 + medroxyprogesterone acetate, effect on ovulation, 79

Screening procedures, combined OC use, 125
Second generation OCs, 5
Selectivity of prescription, OCs, 55
Sex steroids, bioavailability, 59
Sociodemographic factors, OC use, 101
Sperm motility, effect of gramicidin + EDTA, 367
Spermicidal action, NIM-76, 373
Spermicidal activity, nonoxynol-9 oligomers, 39
Spermicidal tests, review, 131

Sterilization,
Filshie clips, 309
psychological effects, 345
quinacrine pellets, 181
Sterilization reversal, factors associated with request, 159

Tamoxifen, effect on uterine cells (rat), 259
TCu 380A, 33, 287
Third generation OCs, 5, 55
Tracking basal body temperatures, 319
Tubal sterilization regret, risk factors, 159

Uniplant implant contraceptive, 213, 281, 313
Uterine cells, effect of antiestrogens (rat), 259

Vaginal ultrasound, placement of TCu 380A, 287
Venous thromboembolism, OC use, 1, 5, 55, 193